U.S. Markets closed

Hemispherx achieves high ranking in sensitivity testing against MERS/SARS

Hemispherx Biopharma announced that a new publication abstract in Infectious Disorder Drug Targets is available for review as described in PubMed on July 16, and proposes that the Middle East Respiratory Syndrome, or MERS,/Severe Acute Respiratory Syndrome, or SARS, coronaviruses, or CoV, may be most effectively inhibited by interferons, or IFNs, and an IFN inducer. The article, entitled "Sensitivity of SARS/MERS CoV to Interferons and Other Drugs Based on Achievable Serum Concentrations in Humans", is authored by Hemispherx scientists. It is suggested that correcting a viral induced defect in immunity may be the first significant way to decrease MERS/SARS associated mortality. Recent Hemispherx collaborations with the National Institutes of Health, or NIH, specifically National Institutes of Allergy and Infectious Disease, or NIAID, using human cells in culture suggest that Alferon N may be effective either as a preventative or treatment of early MERS infection. Subsequently, similar positive inhibitory results with Alferon N were obtained at the University of Texas.